Shots:

• Novavax has signed a non-binding Heads of Terms document with the Australian Government to supply 40M doses of NVX-CoV2373 for the Australian community
• The delivery will start as early as H1’21- following the completion of P-III study and the TGA’s approval of the vaccine. The vaccine regimen is expected to require two doses per individual- administered 21 days apart.
• NVX-CoV2373 is evaluated in P-ll trial in the UK and 2 ongoing P-ll studies that began in Aug’2020- a P-llb trial in SA- and a P-l/ll continuation in the US and Australia. Additionally- Novavax has multiple agreements for the supply of NVX-CoV2373 directly to the US- UK- Canada- and through partnerships- supply to Japan- South Korea- and India

  Ref: GlobeNewswire | Image: MediCircle